Compare UVSP & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVSP | IVA |
|---|---|---|
| Founded | 1876 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 983.8M | 883.8M |
| IPO Year | 1994 | N/A |
| Metric | UVSP | IVA |
|---|---|---|
| Price | $41.35 | $3.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $36.67 | $16.20 |
| AVG Volume (30 Days) | 150.1K | ★ 499.7K |
| Earning Date | 04-22-2026 | 03-30-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 21.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $328,056,000.00 | N/A |
| Revenue This Year | $11.65 | N/A |
| Revenue Next Year | $4.77 | $751.20 |
| P/E Ratio | $42.93 | ★ N/A |
| Revenue Growth | ★ 9.64 | N/A |
| 52 Week Low | $27.91 | $2.94 |
| 52 Week High | $41.77 | $7.98 |
| Indicator | UVSP | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 69.30 | 30.00 |
| Support Level | $32.00 | $3.77 |
| Resistance Level | N/A | $4.67 |
| Average True Range (ATR) | 0.92 | 0.31 |
| MACD | 0.13 | -0.12 |
| Stochastic Oscillator | 89.12 | 8.17 |
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.